These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy of different doses of recombinant human growth hormone in the treatment of short stature in children born small for gestational age].
    Author: Qie D, Yang F.
    Journal: Zhongguo Dang Dai Er Ke Za Zhi; 2016 Mar; 18(3):247-53. PubMed ID: 26975824.
    Abstract:
    OBJECTIVE: To investigate the efficacy and safety of different doses of recombinant human growth hormone (rhGH) in the treatment of short stature in children born small for gestational age (SGA). METHODS: A total of 37 children with short stature born SGA were enrolled, and based on the dose of rhGH treatment, they were divided into low-dose rhGH group (0.1-0.15 IU/kg daily) and high-dose rhGH group (0.16-0.2 IU/kg daily). The changes in height standard deviation score (ΔHtSDS), height velocity (HV), serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3), and fasting blood glucose at 3, 6, 9, 12, and 24 months after treatment were compared between the two groups. RESULTS: ΔHtSDS and HV both increased after the treatment with high- and low-dose rhGH, but ΔHtSDS and HV in the high-dose rhGH group were significantly higher than in the low-dose rhGH group 9, 12 and 24 months after treatment (P<0.05). Both high- and low-dose rhGH treatment increased serum levels of IGF-1 and IGFBP-3. Serum levels of IGF-1 and IGFBP-3 were positively correlated with HtSDS in both groups. One child each in the high- and low-dose rhGH groups experienced transient slight increase in fasting blood glucose (6.1 mmol/L). There were no cases of abnormal thyroid function. CONCLUSIONS: rhGH has good efficacy in the treatment of short stature in children born SGA, with few adverse events, and high-dose rhGH has some advantages over low-dose rhGH. 目的: 研究不同剂量重组人生长激素(rhGH)治疗小于胎龄儿(SGA)矮小症的效果和安全性。 方法: 收集SGA矮小症患儿37例, 并根据使用剂量分为2组:小剂量(每日0.1~0.15 IU/kg)rhGH治疗组和大剂量rhGH治疗组(每日0.16~0.2 IU/kg), 比较两组患儿治疗后3、6、9、12及24个月时身高标准差的增长值(ΔHtSDS)、生长速率(HV)、血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-3(IGFBP-3)水平及空腹血糖等指标的变化。 结果: 大、小剂量rhGH治疗后ΔHtSDS及HV均有提高, 但大剂量组治疗后9、12及24个月时ΔHtSDS及HV均高于小剂量组(P＜0.05)。大剂量和小剂量的rhGH治疗均使血清IGF-1和IGFBP-3水平提高, 且血清IGF-1和IGFBP-3水平与HtSDS呈正相关。大小剂量组各有1例患儿出现一过性空腹血糖轻微升高(均为6.1 mmol/L); 两组甲状腺功能均无异常。 结论: rhGH治疗SGA矮小症效果确切, 不良反应少, 其中大剂量较小剂量治疗更具优势。
    [Abstract] [Full Text] [Related] [New Search]